CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 917,876	$ 812,733
Marketable securities	765,642	596,847
Accounts receivable - trade, net	1,534,324	1,538,642
Accounts receivable from Sanofi	243,238	193,684
Accounts receivable from Bayer	261,685	242,014
Inventories	928,553	726,138
Prepaid expenses and other current assets	163,599	224,972
Total current assets	4,814,917	4,335,030
Marketable securities	2,044,703	1,486,494
Property, plant, and equipment, net	2,461,614	2,358,605
Deferred tax assets	545,077	506,291
Other noncurrent assets	85,669	77,866
Total assets	9,951,980	8,764,286
Current liabilities:
Accounts payable	171,906	178,183
Accrued expenses and other current liabilities	670,709	637,162
Total current liabilities	1,331,190	1,135,483
Capital and facility lease obligations	705,903	703,453
Other noncurrent liabilities	190,020	152,073
Total liabilities	2,765,554	2,620,208
Stockholders' equity:
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	0	0
Additional paid-in capital	3,712,599	3,512,833
Retained earnings	3,839,179	2,946,733
Accumulated other comprehensive (loss) income	(11,612)	640
Treasury Stock, at cost; 3,885,469 shares in 2018 and 3,763,868 shares in 2017	(353,852)	(316,240)
Total stockholders' equity	7,186,426	6,144,078
Total liabilities and stockholders' equity	9,951,980	8,764,286
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	110	110
Sanofi
Current liabilities:
Deferred revenue, current	308,179	177,746
Deferred revenue, noncurrent	339,040	379,936
Other
Current liabilities:
Deferred revenue, current	180,396	142,392
Deferred revenue, noncurrent	$ 199,401	$ 249,263